Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

109.30
+0.95000.88%
Post-market: 109.300.00000.00%17:08 EDT
Volume:1.04M
Turnover:112.60M
Market Cap:9.09B
PE:-34.03
High:110.04
Open:106.52
Low:104.19
Close:108.35
52wk High:130.05
52wk Low:55.26
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.09
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.02
PE(LYR):-29.62

Loading ...

Kymera Therapeutics initiated with an Outperform at Raymond James

TIPRANKS
·
1 hour ago

Kymera Therapeutics is Maintained at Buy by Citigroup

Dow Jones
·
Oct 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $150 from $135

THOMSON REUTERS
·
Oct 05

Kymera Therapeutics CEO Nello Mainolfi Disposes of USD 3.39 Million in Common Shares

Reuters
·
Oct 02

JPMorgan SMid biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 02

Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan

TIPRANKS
·
Sep 28

Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
Sep 24

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Kymera Therapeutics, Inc. : Stifel Raises Target Price to $152 from $132

THOMSON REUTERS
·
Sep 22

US Research Roundup-Boeing, Twilio, WP Carey

Reuters
·
Sep 22

Kymera Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Sep 16

Kymera Therapeutics Price Target Raised to $144.00/Share from $123.00 by B of a Securities

Dow Jones
·
Sep 15

BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

MT Newswires Live
·
Sep 14

Wolfe upgrades Kymera Therapeutics to Outperform on potential upside

TIPRANKS
·
Sep 10

Kymera Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Sep 10

J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
Sep 04

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
Sep 03

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

MT Newswires Live
·
Sep 02

U.S. Research Roundup-Adobe, Dell Technologies, Zscaler

Reuters
·
Sep 02

Kymera Therapeutics, Inc. : JP Morgan Raises Target Price to $140 from $121

THOMSON REUTERS
·
Sep 02